174 related articles for article (PubMed ID: 23054562)
1. Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET-PET.
Niyazi M; Jansen N; Ganswindt U; Schwarz SB; Geisler J; Schnell O; Büsing K; Eigenbrod S; la Fougère C; Belka C
J Neurooncol; 2012 Dec; 110(3):389-95. PubMed ID: 23054562
[TBL] [Abstract][Full Text] [Related]
2.
Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M
J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
Bashir A; Brennum J; Broholm H; Law I
J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
5. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.
Jansen NL; Suchorska B; Wenter V; Eigenbrod S; Schmid-Tannwald C; Zwergal A; Niyazi M; Drexler M; Bartenstein P; Schnell O; Tonn JC; Thon N; Kreth FW; la Fougère C
J Nucl Med; 2014 Feb; 55(2):198-203. PubMed ID: 24379223
[TBL] [Abstract][Full Text] [Related]
6. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
[TBL] [Abstract][Full Text] [Related]
7. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
8. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of
Moller S; Law I; Munck Af Rosenschold P; Costa J; Poulsen HS; Engelholm SA; Engelholm S
Radiother Oncol; 2016 Oct; 121(1):132-137. PubMed ID: 27622554
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and robustness of dynamic
Debus C; Afshar-Oromieh A; Floca R; Ingrisch M; Knoll M; Debus J; Haberkorn U; Abdollahi A
Sci Rep; 2018 Oct; 8(1):14760. PubMed ID: 30283013
[TBL] [Abstract][Full Text] [Related]
11. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.
Pöpperl G; Götz C; Rachinger W; Gildehaus FJ; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1464-70. PubMed ID: 15248032
[TBL] [Abstract][Full Text] [Related]
12. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
[TBL] [Abstract][Full Text] [Related]
13. Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma.
Pöpperl G; Götz C; Rachinger W; Schnell O; Gildehaus FJ; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):792-800. PubMed ID: 16550381
[TBL] [Abstract][Full Text] [Related]
14. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma.
Jansen NL; Suchorska B; Wenter V; Schmid-Tannwald C; Todica A; Eigenbrod S; Niyazi M; Tonn JC; Bartenstein P; Kreth FW; la Fougère C
J Nucl Med; 2015 Jan; 56(1):9-15. PubMed ID: 25537990
[TBL] [Abstract][Full Text] [Related]
16. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas.
Jansen NL; Schwartz C; Graute V; Eigenbrod S; Lutz J; Egensperger R; Pöpperl G; Kretzschmar HA; Cumming P; Bartenstein P; Tonn JC; Kreth FW; la Fougère C; Thon N
Neuro Oncol; 2012 Dec; 14(12):1473-80. PubMed ID: 23090986
[TBL] [Abstract][Full Text] [Related]
17. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.
Mehrkens JH; Pöpperl G; Rachinger W; Herms J; Seelos K; Tatsch K; Tonn JC; Kreth FW
J Neurooncol; 2008 May; 88(1):27-35. PubMed ID: 18217207
[TBL] [Abstract][Full Text] [Related]
18. Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients.
Galldiks N; Unterrainer M; Judov N; Stoffels G; Rapp M; Lohmann P; Vettermann F; Dunkl V; Suchorska B; Tonn JC; Kreth FW; Fink GR; Bartenstein P; Langen KJ; Albert NL
Neuro Oncol; 2019 Oct; 21(10):1331-1338. PubMed ID: 31077276
[TBL] [Abstract][Full Text] [Related]
19. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.
Hutterer M; Nowosielski M; Putzer D; Jansen NL; Seiz M; Schocke M; McCoy M; Göbel G; la Fougère C; Virgolini IJ; Trinka E; Jacobs AH; Stockhammer G
Neuro Oncol; 2013 Mar; 15(3):341-51. PubMed ID: 23335162
[TBL] [Abstract][Full Text] [Related]
20. Potential for differentiation of glioma recurrence from radionecrosis using integrated
Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
